Skip to main content
SpringerLink
Log in

Economics of Therapy for Acute Coronary Syndromes

  • Chapter
Cardiovascular Health Care Economics

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 363 Accesses

Abstract

Acute coronary syndromes (ACS), defined as acute myocardial infarction (MI) and unstable angina, share a number of common features. These include an underlying ruptured or eroded atherosclerotic coronary plaque as the most frequent initiating pathophysiologic event, similar clinical manifestations, and a clinical course that lasts for usually no more than 30 days (1). The management of ACS is hospital-based and often resource-intensive. Thus, economic analyses of these syndromes and their therapies are typically focused on the initial hospitalization. Conceptually, therefore, it is useful to divide the costs of care for ACS into five major categories (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193–1209.

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001; 103: 2862–2866.

    Article  PubMed  CAS  Google Scholar 

  3. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. Circulation 2001; 103: 2987–2992.

    Article  PubMed  CAS  Google Scholar 

  4. Mark DB, Hlatky MA, Calif RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–1424.

    Article  PubMed  CAS  Google Scholar 

  5. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative managment strategy. Veterans Affiars Non-Q-Wave Infarction Strategies in Hospital (VANQWISH). N Engl J Med 1998; 338: 1785–1792.

    Article  PubMed  CAS  Google Scholar 

  6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/Illa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887.

    Article  PubMed  CAS  Google Scholar 

  7. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708–715.

    Article  Google Scholar 

  8. Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162–1168.

    Article  PubMed  CAS  Google Scholar 

  9. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716–722.

    Google Scholar 

  10. Tung CY, Granger CB, Sloan MA, et al. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. Circulation 1999; 99: 370–376.

    Article  PubMed  CAS  Google Scholar 

  11. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322.

    Google Scholar 

  12. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ (ed.) Textbook of Cardiovascular Medicine. Lippincott Williams & Wilkins, Philadelphia, PA, 2002, pp. 957–979.

    Google Scholar 

  13. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993; 9 (6): 553–558.

    PubMed  CAS  Google Scholar 

  14. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327: 7–13.

    Article  PubMed  CAS  Google Scholar 

  15. White HD. Thrombolytic therapy in the elderly. Lancet 2000; 356: 2028–2030.

    Article  PubMed  CAS  Google Scholar 

  16. de Boer MJ, Ottervanger JP, van’t Hof AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002; 39: 1723–1728.

    Article  PubMed  Google Scholar 

  17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.

    Google Scholar 

  18. Mark DB, Hlatky MA, Calif RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–1424.

    Article  PubMed  CAS  Google Scholar 

  19. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002; 106: 516–520.

    Google Scholar 

  20. Topol EJ, Ohman EM, Armstrong PW, et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation 2000; 102: 1761–1765.

    Article  PubMed  CAS  Google Scholar 

  21. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905–1914.

    Article  PubMed  CAS  Google Scholar 

  22. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605–613.

    Google Scholar 

  23. The GUSTO IIb Angioplasty Substudy Investigators. An international randomized trial of 1138 patients comparing primary coronary angioplasty versus tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621–1628.

    Google Scholar 

  24. Mark DB, Granger CB, Ellis SG, et al. Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: Results From the GUSTO II Randomized Trial. (Abstr). Circulation 1996; 94: 168A.

    Google Scholar 

  25. Every NR, Parsons LS, Hlatky MA, et al. for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335: 1253–1260.

    Article  PubMed  CAS  Google Scholar 

  26. Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with primary percutaneous trans-luminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998; 31: 1240–1245.

    Article  PubMed  CAS  Google Scholar 

  27. Grines CL, Westerhausen DR, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction. The Air Primary Angioplasty in Myocardial Infarction Study. J Am Coll Cardiol 2002; 39: 1713–1719.

    Article  PubMed  Google Scholar 

  28. Cannon CP, Bairn DS. Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2002; 39: 1720–1722.

    Article  PubMed  Google Scholar 

  29. Ashmore RC, Luckasen GJ, Larson DG, et al. Immediate angioplasty for acute myocardial infarction: a community hospital’s experience. J Invasive Cardiol 1999; 11: 61–65.

    PubMed  CAS  Google Scholar 

  30. Lieu TA, Lundstrom RJ, Ray GT, et al. Initial cost of primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1996; 28: 882–889.

    Article  PubMed  CAS  Google Scholar 

  31. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341: 1949–1956.

    Article  PubMed  CAS  Google Scholar 

  32. Cohen DJ, Taira DA, Berezin RH, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial. Circulation 2001; 104: 3039–3045.

    Article  PubMed  CAS  Google Scholar 

  33. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–741.

    Article  PubMed  CAS  Google Scholar 

  34. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without-abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–966.

    Article  PubMed  CAS  Google Scholar 

  35. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.

    Article  PubMed  CAS  Google Scholar 

  36. ISIS-2 (Second International Study of Infarct Survival). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360.

    Google Scholar 

  37. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800=1806.

    Google Scholar 

  38. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1997; 348: 1329–1339.

    Google Scholar 

  39. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

    Article  PubMed  CAS  Google Scholar 

  40. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–1924.

    Google Scholar 

  41. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189–198.

    Article  PubMed  CAS  Google Scholar 

  42. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med 1998; 339: 436–443.

    Google Scholar 

  43. Mark DB, Harrington RA, Lincoff AM, et al. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation 2000; 101: 366–371.

    Article  PubMed  CAS  Google Scholar 

  44. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. Eur Heart J 2002; 23: 50–58.

    Article  PubMed  CAS  Google Scholar 

  45. FRISCII Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999; 354: 701–707.

    Google Scholar 

  46. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–1608.

    Article  PubMed  CAS  Google Scholar 

  47. Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for prevent- ing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308–314.

    Article  PubMed  CAS  Google Scholar 

  48. Mark DB, Cowper PA, Berkowitz S, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–1707.

    Article  PubMed  CAS  Google Scholar 

  49. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782.

    Google Scholar 

  50. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet 2002;359:294–302.

    Google Scholar 

  51. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000; 284: 2748–2754.

    Article  PubMed  CAS  Google Scholar 

  52. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669–677.

    Article  PubMed  CAS  Google Scholar 

  53. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–919.

    Article  PubMed  CAS  Google Scholar 

  54. Franzosi MG, Maggioni AP, Santoro E, et al. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. Pharmacoeconomics 1998; 13: 337–346.

    Article  PubMed  CAS  Google Scholar 

  55. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.

    Google Scholar 

  56. Lamy A, Gafni A, Pogue J, Yusuf S. Cost-effectiveness of ramipril in high risk patients: analysis of the HOPE study. (Abstr). Can J Cardio12000;16(Suppl F):233F.

    Google Scholar 

  57. National Cholesterol Education Program (Adult Treatment Panel III). Detection, evaluation, and treatment of high blood cholesterol in adults. NIH Publication, No. 01–3670, 2001, Bethesda, MD.

    Google Scholar 

  58. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

    Google Scholar 

  59. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Group. Circulation 1996; 93: 1796–1802.

    Article  PubMed  CAS  Google Scholar 

  60. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332–336.

    Article  PubMed  CAS  Google Scholar 

  61. Grines CL, Marsalese DL, Brodie BR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998; 31: 967–972.

    Article  PubMed  CAS  Google Scholar 

  62. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141: 727–734.

    Article  PubMed  CAS  Google Scholar 

  63. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988; 260: 945–950.

    Article  PubMed  CAS  Google Scholar 

  64. O’Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234–244.

    Article  PubMed  Google Scholar 

  65. Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol 1993; 72: 154–161.

    Article  PubMed  CAS  Google Scholar 

  66. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997; 17: 222–231.

    Article  PubMed  CAS  Google Scholar 

  67. Eisenstein EL, Shaw LK, Anstrom KJ, et al. Assessing the clinical and economic burden of coronary artery disease: 1986–1998. Med Care 2001; 39: 824–835.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daniel B. Mark MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    William S. Weintraub MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mark, D.B. (2003). Economics of Therapy for Acute Coronary Syndromes. In: Weintraub, W.S. (eds) Cardiovascular Health Care Economics. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-398-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-398-9_11

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9784-7

  • Online ISBN: 978-1-59259-398-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation